Want to see WOK full AI Analyst Report?
Top Page
WORK Medical Technology Group LTD
(NASDAQ:WOK)
Select Model
Select Model
Rating:47Neutral
Price Target:
$1.50
▼(-28.57% Downside)
Action:Reiterated
Date:02/07/26
The score is held back primarily by deteriorated profitability and contracting revenue, alongside bearish technical momentum. Offsetting this, leverage improved and cash flow rebounded in the latest year, but the lack of meaningful valuation support (negative earnings and no dividend data) keeps the overall profile below average.
Positive Factors
Improved leverage / balance sheet health
Lower debt-to-equity materially reduces balance-sheet risk and interest burden, giving the company more financial flexibility. Over the next 2–6 months this supports capacity to fund operations, invest selectively or withstand revenue headwinds without immediate refinancing pressure.
Negative Factors
Contracting revenue and persistent losses
Declining top line and negative margins indicate structural demand or competitive challenges that limit profitable scale. Persisting revenue contraction reduces ability to leverage fixed costs, undermines long-term return on capital, and constrains reinvestment without clear demand recovery.
Read all positive and negative factors
Positive Factors
Negative Factors
Improved leverage / balance sheet health
Lower debt-to-equity materially reduces balance-sheet risk and interest burden, giving the company more financial flexibility. Over the next 2–6 months this supports capacity to fund operations, invest selectively or withstand revenue headwinds without immediate refinancing pressure.
Read all positive factors
WORK Medical Technology Group LTD (WOK) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$5.37M
Dividend YieldN/A
Average Volume (3M)33.96M
Price to Earnings (P/E)―
Beta (1Y)0.87
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees238
SectorHealthcare
Sector Strength45
IndustryMedical - Specialties
Share Statistics
EPS (TTM)-9.58
Shares Outstanding2,416,538
10 Day Avg. Volume36,631,792
30 Day Avg. Volume33,957,643
Financial Highlights & Ratios
PEG Ratio-54.59
Price to Book (P/B)1.18K
Price to Sales (P/S)2203.94
P/FCF Ratio4.42K
Enterprise Value/Market Cap0.44
Enterprise Value/Revenue0.24
Enterprise Value/Gross Profit1.01
Enterprise Value/Ebitda-1.69
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
WORK Medical Technology Group LTD Business Overview & Revenue Model
Company Description
WORK Medical Technology Group LTD, through with its subsidiaries, manufactures and sells medical consumables and devices in the People's Republic of China and internationally. The company offers medical face masks, artery compression tourniquets, ...
How the Company Makes Money
WORK Medical Technology Group LTD generates revenue through multiple streams, primarily from the sale of its medical devices and digital health solutions. The company sells its products to hospitals, clinics, and healthcare providers, which consti...
WORK Medical Technology Group LTD Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
62
Positive
Cash Flow
55
Neutral
| Breakdown | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 9.85M | 11.51M | 13.57M | 19.71M | 45.86M |
| Gross Profit | 2.34M | 2.87M | 4.14M | 4.42M | 8.64M |
| EBITDA | 339.37K | -1.71M | 2.08M | 4.72M | 11.87M |
| Net Income | -1.07M | -3.49M | 112.03K | 865.21K | 5.96M |
Balance Sheet | |||||
| Total Assets | 33.16M | 36.25M | 29.96M | 25.54M | 30.66M |
| Cash, Cash Equivalents and Short-Term Investments | 4.09M | 6.56M | 1.60M | 731.18K | 508.71K |
| Total Debt | 6.45M | 13.47M | 9.10M | 6.30M | 6.60M |
| Total Liabilities | 11.99M | 20.18M | 18.97M | 14.35M | 19.26M |
| Stockholders Equity | 18.35M | 13.19M | 9.88M | 10.00M | 10.04M |
Cash Flow | |||||
| Free Cash Flow | 4.91M | -11.49M | 1.63M | -4.27M | -7.24M |
| Operating Cash Flow | 6.24M | -2.23M | 2.21M | -2.26M | -7.18M |
| Investing Cash Flow | -7.61M | -9.06M | -583.30K | -1.35M | -60.00K |
| Financing Cash Flow | -898.21K | 15.66M | -728.72K | 3.57M | 7.99M |
WORK Medical Technology Group LTD Technical Analysis
Negative
2.10
Price Trends
78.29
Negative
101.94
Negative
55647.34
Negative
Market Momentum
-21.76
Negative
39.53
Neutral
5.10
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For WOK, the sentiment is Negative. The current price of 2.1 is below the 20-day moving average (MA) of 7.05, below the 50-day MA of 78.29, and below the 200-day MA of 55647.34, indicating a bearish trend. The MACD of -21.76 indicates Negative momentum. The RSI at 39.53 is Neutral, neither overbought nor oversold. The STOCH value of 5.10 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for WOK.
WORK Medical Technology Group LTD Risk Analysis
WORK Medical Technology Group LTD disclosed 83 risk factors in its most recent earnings report. WORK Medical Technology Group LTD reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
WORK Medical Technology Group LTD Peers Comparison
UnderperformOutperform
Sector (51)
WOK
WORK Medical Technology Group LTD
2.22
-690,097.78
-100.00%
GCTK
GlucoTrack
0.33
-5.67
-94.50%
LUCY
Innovative Eyewear, Inc.
0.78
-1.34
-63.07%
WORK Medical Technology Group LTD Corporate Events
WORK Medical Technology Group Plans Major Capital Restructuring Ahead of February 25 AGM
Feb 10, 2026
WORK Medical Technology Group LTD has called its annual general meeting of shareholders for February 25, 2026, in Hangzhou with virtual participation available, targeting both Class A and Class B shareholders. The meeting will consider a sweeping ...
WORK Medical Technology Group Sells New Class B Shares to COO’s Entity, Consolidating Voting Control
Jan 5, 2026
On December 30, 2025, WORK Medical Technology Group LTD entered into a securities purchase agreement with LWY GROUP LTD, an existing shareholder wholly owned by the company’s chief operating officer, Baiming Yu, for the issuance and sale of ...
WORK Medical Technology Group Executes 100-for-1 Share Consolidation to Maintain Nasdaq Listing
Dec 30, 2025
On October 21, 2025, WORK Medical Technology Group LTD shareholders approved resolutions authorizing one or more consolidations of the company’s authorized, issued and outstanding ordinary shares within a range of 2:1 to 250:1, along with ad...
WORK Medical Technology Group Enters Sales Agreement to Raise $200 Million
Nov 24, 2025
On November 20, 2025, WORK Medical Technology Group LTD announced a new sales agreement with AC Sunshine Securities, LLC, allowing the company to offer and sell Class A ordinary shares through the sales agent. The agreement enables the company to ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.